益心汤对冠心病患者血清脂质代谢紊乱的调节作用

Clinical and Experimental Study on Its Regulatory Function of Yi Xin Decoction (Heart-Nourishing Decoction) to Lipids Metabolic Disturbance in CHD Patients

本研究观察了中药益心汤辨证加味对74例冠心病患者脂质代谢紊乱的调节作用,并进行动物实验研究。结果表明益心汤具有降低冠心病患者apoB、TG的作用;同时具有升高apoA-1,HDL-C的作用;而且降低apoB和升高HDL-C的作用优于烟酸肌醇酯合用脉通治疗的对照组。其作用机制是抑制内源性胆固醇的合成;增加肠道中胆酸的排泄;直接或间接地促进肝脏中胆固醇向胆酸转化。

In this research, 74 patients with coronary heart disease (CHD) were grouped in matched-pair,one group took orally Inositol and Mai Tong(脉通) as the control group, the other group took orally Yi Xin Decoction as the tested group. Indices, i. e. serum levels of apolipoprotein A-l(Apo A-1),apolipoprotein B (Apo-B), high density lipoprotein cholesterol (HDL-c), high density lipoprotein subcomponent cholesterol (HDL2-c), B-lipoprotein (B-P),total cholesterol (Tch), triglyceride (TG)were measured before and after treatment for 28 days; the results showed that the patients with CHD have prominant derangement of lipid metabolism, which is similar to previous reports. Yi Xin Decoction modified according to Syndrome Differentiation, produced the effect of decreasing the serum Apo-B levels and TG. It also increased Apo-A-1, HDL-c and HDL2-c respectively. Moreover the effect of lowering Apo-B and raising HDL-c in the Yi Xin Decoction group was better than that in the control group. There was no side effect at all: all these indicated that Yi Xin Decoction has a remarkable function of regulating the disturbatice of lipid metabolism in CHD patients. In order to further investigate the curative effect of Yi Xin Decoction and elucidate its mechanism, the authors have also investigated Yi Xin Decoction on the experimental mice with hyperlipemia. The result Showed that Tch and TG in atromid and Yi Xin Decoction group reduced after medication,P<0.01. In comparing with control group, the HDL-c and acidic cholesterol in stool Yi Xin Decoction group rose, P<0.05. The above study has provided reliable basis for the clinical applica-tion of Yi Xin Decoction and also a new medicine to regulate disturbance of lipid metabolism for CHD patients.